Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 3

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Neuroendocrine Tumors 2Pancreatic Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 641pembrolizumab 585Magnetic Resonance Spectroscopy 555Carboplatin 431Cyclophosphamide 381Cisplatin 379Biopsy 376Nivolumab 315Paclitaxel 314Gemcitabine 308Radiotherapy 286Bevacizumab 235Dexamethasone 218fludarabine 206Docetaxel 194durvalumab 189Oxaliplatin 189venetoclax 187Rituximab 175Fluorouracil 175atezolizumab 172Pemetrexed 167Capecitabine 164Radiosurgery 162Doxorubicin 162Radiation 160Ipilimumab 146Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
lanreotide × 90 days × Clear all
NCT05048901 2026-04-09

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
49 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06807437 2026-03-31

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

SWOG Cancer Research Network

Phase 3 Recruiting
274 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡